• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[慢性丙型肝炎患儿对病因导向性和致病性治疗的免疫反应特征]

[Characteristics of immune response to etiotropic and pathogenetic therapy in children with chronic hepatitis C].

作者信息

Vasil'eva D K, Goriacheva L G, Monakhova N E

出版信息

Eksp Klin Farmakol. 2011;74(12):33-5.

PMID:22379880
Abstract

Features of the immune response of children with chronic hepatitis C to the antiviral and pathogenetic therapy have been studied. It is shown that the antiviral therapy is accompanied by stimulation of the immune response as manifested by the synthesis of cytokines (IL-4, IFN-alpha, IFN-gamma) with retention of increased production of IFN-a for more than two years after the end of the course of treatment. In children that previously received interferon inductor (cycloferon) for 12 months, high level of IFN-a production is retained, which ensures antiviral protection. Phytotherapy did not influence the production of cytokines.

摘要

对慢性丙型肝炎患儿对抗病毒和发病机制治疗的免疫反应特征进行了研究。结果表明,抗病毒治疗伴随着免疫反应的刺激,表现为细胞因子(IL-4、IFN-α、IFN-γ)的合成,且在治疗疗程结束后两年多的时间里,IFN-α的产生持续增加。在先前接受干扰素诱导剂(环孢菌素)治疗12个月的儿童中,IFN-α的高水平产生得以维持,从而确保了抗病毒保护作用。植物疗法并未影响细胞因子的产生。

相似文献

1
[Characteristics of immune response to etiotropic and pathogenetic therapy in children with chronic hepatitis C].[慢性丙型肝炎患儿对病因导向性和致病性治疗的免疫反应特征]
Eksp Klin Farmakol. 2011;74(12):33-5.
2
[Efficiency of using cycloferon as part of combined therapy for chronic hepatitis C (a review of multicenter clinical trials)].[将环孢素作为慢性丙型肝炎联合治疗一部分的使用效率(多中心临床试验综述)]
Ter Arkh. 2010;82(10):78-81.
3
[Rational pharmacotherapy and correction of immunity disorders in children with chronic hepatitis (clinical review)].[慢性肝炎患儿的合理药物治疗与免疫紊乱纠正(临床综述)]
Antibiot Khimioter. 2010;55(5-6):50-7.
4
[Efficacy of combined immunocorrection in the treatment of chronic viral hepatitis C].[联合免疫纠正疗法治疗慢性丙型病毒性肝炎的疗效]
Ter Arkh. 2012;84(6):60-5.
5
[Clinical efficiency of reamberin - cycloferon combination in treatment of hepatic cirrhosis associated with chronic HCV infection].[雷姆贝林-环孢素联合治疗慢性丙型肝炎病毒感染相关肝硬化的临床疗效]
Eksp Klin Farmakol. 2012;75(8):34-8.
6
[Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].[慢性丙型病毒性肝炎治疗“金标准”中的免疫调节剂]
Antibiot Khimioter. 2008;53(3-4):18-22.
7
[Minimization of endogenous intoxication syndrome by individual choice of drugs for therapy of chronic hepatitis].[通过个体化选择药物治疗慢性肝炎来减轻内源性中毒综合征]
Antibiot Khimioter. 2011;56(3-4):46-50.
8
Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).干扰素-γ:生物学功能与丙型肝炎病毒治疗(I/II型)(共两部分,此为第二部分)
Clin Ter. 2006 Sep-Oct;157(5):457-68.
9
[Cytokinin inducing and antiviral activity of cycloferon on experimental herpetic infection].
Zh Mikrobiol Epidemiol Immunobiol. 2003 Jul-Aug(4):105-7.
10
[Dose-dependent interferon-induction activity and pharmacokinetics of cycloferon in healthy humans].[环孢素在健康人体中的剂量依赖性干扰素诱导活性及药代动力学]
Eksp Klin Farmakol. 2012;75(1):23-6.